← Leaderboards
Mark S Berger
Actinium Pharmaceuticals, Inc.
$189,195
Attributed
$378,389
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$378,389 · 1
By mechanism
R42$378,389 · 1
Top collaborators
- Mark B Geyer1 shared
Most similar at Actinium Pharmaceuticals, Inc.
Same institution · by research overlap
- Mark B Geyer$1,255,803
- Avinash Desai$865,308
Others in their field
Other Emerging Leaders on “Acute Myelocytic Leukemia”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Leonard Freedman · Leidos Biomedical Research, Inc.$12,430,568
- Crystal Mackall · Children'S Hosp Of Philadelphia$6,450,142
- Christopher A Miller · Washington University$5,424,298
- Eric Padron · H. Lee Moffitt Cancer Ctr & Res Inst$5,329,699
- Kelly Diringer Getz · University Of Pennsylvania$4,068,250
Research focus
Acute Myelocytic LeukemiaAdoptedAdoptive Cell TransfersAdultAgedAntibodiesAntibody-Drug ConjugatesAutologousB-Cell Acute Lymphoblastic LeukemiaBehavior TherapyBiodistributionBloodBone MarrowCancer CellCd19 AntigensCd19 GeneCd28 GeneCellsCerebral EdemaCerebrospinal FluidChemotherapyChimeric Antigen ReceptorClinical ResearchActinium